Understand the source comparison
Mod GRF 1-29 Versus CJC-1295 with DAC: Research Context Determines the Right Tool
The nomenclature surrounding these peptides creates persistent confusion in research literature and laboratory protocols. "CJC-1295" was originally coined to describe the DAC-conjugated form of Mod GRF 1-29. A version where the peptide is covalently bonded to
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The nomenclature surrounding these peptides creates persistent confusion in research literature and laboratory protocols. "CJC-1295" was originally coined to describe the DAC-conjugated form of Mod GRF 1-29. A version where the peptide is covalently bonded to Drug Affinity Complex (DAC), a synthetic molecule that binds serum albumin and dramatically extends the peptide's half-life to 6–8 days. Over time, suppliers began marketing Mod GRF 1-29 (the non-conjugated form) as "CJC-1295 No DAC" or "CJC-1295 without DAC" to differentiate it from the long-acting version, but this naming convention obscures the fact that these are functionally distinct compounds.
- Mod GRF 1-29 and CJC-1295 with DAC produce completely different growth hormone dynamics. Mod GRF 1-29 generates a single, discrete GH pulse lasting 2–3 hours after administration, after which plasma GH returns to baseline. This preserves the body's natural circadian GH rhythm. Endogenous GH secretion occurs in pulses throughout the day, with the largest pulse occurring during slow-wave sleep. Research investigating sleep quality, nocturnal anabolic processes, or circadian hormone regulation requires preservation of this pulsatile pattern, making Mod GRF 1-29 the appropriate tool.
- CJC-1295 with DAC, by contrast, produces sustained GH elevation lasting multiple days. A single 2 mg subcutaneous injection elevates basal GH concentrations for 6–10 days, creating a pharmacological state that does not exist in nature. This sustained elevation suppresses endogenous GHRH secretion through negative feedback. The hypothalamus detects elevated IGF-1 levels and reduces GHRH output accordingly. Over time, this can desensitize pituitary somatotrophs to GHRH stimulation and downregulate GHRH receptor expression.
- The practical consequence: researchers using CJC-1295 with DAC in long-term protocols (12+ weeks) often observe diminishing GH responses over time, even with dose escalation. This tachyphylaxis (reduced response to repeated administration) does not occur with Mod GRF 1-29 because the pulsatile stimulation pattern does not suppress endogenous GHRH secretion. The pituitary gland continues to respond to both endogenous and exogenous GHRH pulses without receptor desensitization.
- From a protocol design standpoint, the choice between Mod GRF 1-29 and CJC-1295 with DAC depends entirely on the research question. If the objective is to produce sustained GH elevation (for example, investigating the effects of chronic GH exposure on liver metabolism or glucose homeostasis), CJC-1295 with DAC may be appropriate. If the objective is to amplify physiological GH pulses, preserve circadian rhythm, or study the effects of pulsatile versus continuous GH on downstream signaling pathways, Mod GRF 1-29 is the correct choice. Conflating the two peptides as interchangeable introduces confounding variables that compromise experimental validity.